Mepolizumab Biosimilar Monoclonal Antibody (IL-5) for Research

Cat No.: GMP-Bios-ab-341

Pre-Made Mepolizumab biosimilar, Whole mAb, Anti-IL5 Antibody: Anti-EDF/IL-5/TRF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Mepolizumab, sold under the brand name Nucala, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES). It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-341-1mg 1mg 3090

Size： 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Mepolizumab biosimilar, Whole mAb, Anti-IL5 Antibody: Anti-EDF/IL-5/TRF therapeutic antibody
INN Name Mepolizumab
TargetIL5
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed1999
Year Recommended2000
CompaniesGlaxoSmithKline;McMaster University;National Institute of Allergy and Infectious Diseases
Conditions ApprovedAsthma;Churg-Strauss syndrome;Hypereosinophilic syndrome
Conditions ActiveChronic obstructive pulmonary disease;Hypereosinophilic syndrome;Nasal polyps;Eosinophilic oesophagitis
Conditions DiscontinuedAtopic dermatitis
Development Techna



About target - IL5

1. Protein Interleukin-5

2. Gene IL5

3. Organism Homo sapiens (Human)

Function
Factor that induces terminal differentiation of late-developing B-cells to immunoglobulin secreting cells.